Volume 27, Issue 5 (10-2019)                   JSSU 2019, 27(5): 1505-1515 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akhondi-Meybodi M. New treatment of hepatitis C (Direct Acting Antiviral). JSSU 2019; 27 (5) :1505-1515
URL: http://jssu.ssu.ac.ir/article-1-4743-en.html
Abstract:   (2799 Views)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat  HCV and eliminated HCV in future
Full-Text [PDF 873 kb]   (847 Downloads)    
Type of Study: Review article | Subject: Infectious Diseases
Received: 2018/11/17 | Accepted: 2019/01/19 | Published: 2019/10/9

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | SSU_Journals

Designed & Developed by : Yektaweb